Description
Semaglutide (GLP-1 Receptor Agonist)
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that has been extensively researched for its effects on weight management, metabolic health, and appetite regulation. As a long-acting GLP-1 analog, semaglutide mimics the action of the natural incretin hormone GLP-1.
Chemical Makeup
Semaglutide is a modified peptide consisting of 31 amino acids with 94% sequence homology to native human GLP-1. The peptide includes modifications that provide protease stability and albumin binding, resulting in a half-life of approximately one week.
Research and Clinical Studies
Semaglutide and Weight Loss
Clinical research has demonstrated that semaglutide produces significant weight loss results. The STEP (Semaglutide Treatment Effect in People with Obesity) trials showed that participants using semaglutide achieved an average weight loss of 14.9% of initial body weight over 68 weeks, compared to 2.4% with placebo. Approximately 86.4% of participants achieved at least 5% weight loss, and 69.1% achieved at least 10% weight loss.
Studies indicate that semaglutide works through multiple mechanisms: reducing appetite and food intake, slowing gastric emptying, and improving satiety signals. These effects result from the peptide’s action on GLP-1 receptors in the brain’s appetite control centers, particularly the hypothalamus and brainstem.
Semaglutide and Metabolic Health
Research shows that semaglutide improves multiple metabolic parameters beyond weight loss. Studies have demonstrated significant improvements in glycemic control, with HbA1c reductions of 1.5-2.0% in subjects with elevated baseline levels. The peptide also shows positive effects on blood pressure, with average reductions of 3-5 mmHg in systolic pressure.
Semaglutide and Cardiovascular Benefits
The SUSTAIN-6 trial demonstrated that semaglutide was associated with a 26% reduction in major adverse cardiovascular events. Research suggests this may be due to improvements in multiple cardiovascular risk factors, including weight, blood pressure, lipid profiles, and inflammatory markers.
Semaglutide is available for research and laboratory purposes only. Please review our Terms and Conditions before placing an order.
References:
1. Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002.
2. Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834-1844.
Reviews
There are no reviews yet.